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INTRODUCTION
The heritable disorders called Ehlers–-
Danlos syndrome (EDS) are as dispa-
rate as they are fascinating. Their
discovery and description has been an
intimate part of the growth of our
understanding of matrix biology. Joint
hypermobility, skin extensibility, ab-
normal scarring, and tissue friability
are the hallmark diagnostic features;
however, McKusick (1956) recognized
that EDS is under-recognized because
when the physical signs are not
‘‘classic’’ the diagnosis may be elusive.
The medical and scientific history of
EDS can be seen in three phases:
clinical characterization, biochemical
and molecular genetic analysis, and
the use of high throughput genomic
analysis to extend the phenotypes.
CREATING THE CLINICAL SPECTRUM
OF EDS
Hippocrates described the features of
this disorder in 400 BC; however, the
first medical description of some of the
characteristics is credited to van Meek’-
ren (1682). Tschernogubow’s presenta-
tion in 1892 seems to have been largely
overlooked in Western Europe, prob-
ably because it was written in Russian.
Weber (1936) is credited with chris-
tening the disorder as EDS in 1936
after Ehlers (1901) and Danlos (1908),
two dermatologists who separately
described affected patients in 1901
and 1908, respectively. The same
year, Georg Sack, a German physician,
described a condition that Barabas
later identified as the arterial type.
McKusick (1956) provided the first
synthesis of the clinical literature on
the multisystemic and variable nature
of EDS in his 1956 hallmark work on
heritable connective tissue disorders.
Over a decade later, Barabas (1967)
proposed at least three distinct sub-
types: classical, varicose, and arterial
on the basis of his experience with 27
affected individuals. He suggested that
the clinical subtypes reflected discrete
etiologies, not simply variable expres-
sions of one disorder. A short time later,
Peter Beighton published a series of
papers from a landmark clinical inves-
tigation of 100 individuals with EDS.
He recognized and expanded Barabas’
work to a classification of five types
(Beighton et al., 1969). The first group
included individuals similar to those
initially described with skin hyper-
extensibility and fragility, with abnor-
mal scarring and bruising, and striking
joint hypermobility (the gravis form).
The second was similar but the skin
findings were less dramatic (mitis). A
hypermobility form in which the joint
findings were striking almost to the
exclusion of skin changes was the third
type. The Sack-Barabas group (the
fourth type) had very severe vascular
fragility and was at risk of arterial
rupture and bowel rupture. The fifth
group was thought to be X-linked and
was characterized by joint hyper-
mobility and intramuscular hemor-
rhage (Table 1).
THE FIRST PHASE OF BIOCHEMICAL
CHARACTERIZATION OF EDS
During the early phase of clinical
characterization, clues to the molecular
basis of any of the forms of EDS were
sparse, with the exception that light
and electron microscopy studies iden-
tified abnormalities in the structure
of collagens in the dermal matrix
(Wechsler and Fisher, 1964; Julkunen
et al., 1970). The dam broke in the
early 1970s as a result of tissue analysis
to assess interactions/cross-links bet-
ween collagen molecules, animal
studies, and use of cultured cells from
selected individuals to examine col-
lagen production. Detailed knowledge
of the structure of cross-links and the
awareness of their importance in tissue
integrity provided the background in
which the study of sisters with hyper-
mobility, soft extensible skin, scoliosis
recalcitrant to surgical intervention,
and ocular globe fragility (Krane et al.,
1972; Steinmann et al., 1975) led to the
identification of lysyl hydroxylase defi-
ciency. In these sisters, hydroxylated
complex cross-links were diminished
and the virtual absence of hydroxyla-
tion of lysyl residues in triple helical
collagen molecules resulted from defi-
ciency of lysyl hydroxylase. Once the
gene (PLOD1) was isolated, sequence
analysis demonstrated inactivating
mutations, the most common of which
was a 7-exon duplication mediated
by Alu–Alu recombination (Heikkinen
et al., 1997). This was one of the very
early demonstrations of the role of
repetitive elements in the genome as
mediators of deletions or duplications.
This disorder, a recessively inherited
condition, was called EDS type VI and
was the first established true disorder
of collagen biosynthesis and structure
in humans.
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Table 1. Classification of EDS
Numerical
type Descriptive type Genes OMIM Inheritance Clinical features and notes
I (Gravis) Classical1 COL5A1 130000 AD Marked joint hypermobility, skin hyperextensibility, bruising,
and abnormal scarring
II (Mitis) COL5A2 130010
III Hypermobility2 TNXB
Largely unknown
130020 AD Marked joint hypermobility, minor skin findings
IV Vascular COL3A1 130050 AD Thin translucent skin, marked bruising, small joint
hypermobility, high risk for rupture of arteries, bowel, and
gravid uterus
VIA Kyphoscoliosis PLOD1 225400 AR Joint hypermobility and kyphoscoliosis recalcitrant to surgical
intervention, risk for arterial rupture
VIB Musculocontractural CHST14 601776 AR Congenital contractures of digits, dysmorphic features,
kyphoscoliosis and hypermobility, hyperextensible thin skin,
ocular involvement
VIIA Arthrochalasia
multiplex congenita
COL1A1 130060 AD Marked joint hypermobility, bilateral congenital hip dislocation
VIIB COL1A2
VIIC Dermatosparaxis ADAMTS2 225410 AR Soft, very fragile skin with late onset skin redundancy, blue
sclerae, joint hypermobility
VIII Periodontitis Probably hetero-
geneous; one
locus at 12p13
130080 AD Periodontal loss, joint hypermobility, soft skin with
characteristic plaque on anterior tibial region
Other
Progeroid B4GALT7 130070 AR
Cardiac valvular COL1A2 225320 AR (null) Cardiac valvular insufficiency, joint hypermobility, skin
hyperextensibility
FKBP14 related FKBP14 614557 AR Marked kyphoscoliosis, hearing loss, myopathy, short stature,
joint hypermobility
Spondylocheiro
dysplastic
SLC39A13 612350 AR Spondyloepiphyseal dysplasia with mild short stature,
hyperelastic thin skin with easy bruising, protuberant eyes,
bluish sclerae, fine wrinkling on palms
Tenascin-X deficient TNXB 606408 AR Joint hypermobility, hyperextensible and sleeve-like character
to skin, marked bruising, normal scarring
Periventricular
heterotopia
FLNA 300537 XL Periventricular heterotopia, joint hypermobility
Poorly characterized, disputed, retired, or reclassified3
V X linked Unknown 305200 XL Joint hypermobility with muscle hemorrhage
VIB Brittle Cornea
syndrome
ZNF469 22920 AR Blue sclerae, corneal rupture, keratoconus, hyperextensible
skin, joint hypermobility
PRDM5 614170
IX Occipital Horn
syndrome
ATP7A 304150 XL Hyperextensible skin and bruising, hernias and bladder
diverticuli, joint hypermobility
X Fibronectin deficient Unknown 225310 ? One reported family with platelet dysfunction and mild features
of EDS
XI Familial Joint Laxity Unknown 147900 AD Retired
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; EDS, Ehlers–Danlos syndrome; XL, X linked.
1Specific mutations in COL1A1 (substitutions of cysteine for arginine residues within the triple helical domain of proa1(I) chains) have been recognized to cause
a form of EDS reminiscent of classical type with joint hypermobility, skin hyperextensibility, bruising and abnormal scarring, and predisposition to aortic
aneurysm.
2One family with a specific mutation in COL3A1 is said to have only joint hypermobility with none of the other consequences seen in EDS type IV.
3We have included these previously identified ‘‘types’’ of EDS for historical perspective. They are not included in most classifications.
MILESTONES | CUTANEOUS BIOLOGY NOVEMBER 2012 E7
Cattle with a curious and severe
form of skin fragility provided the next
step in the identification of human
collagen disorders, as well as insight
into the question of how an essentially
insoluble molecule—collagen—could
be synthesized and secreted from cells.
The bovine disorder, dermatosparaxis,
appeared to be inherited in an auto-
somal recessive manner, and biochem-
ical studies demonstrated that
affected animals failed to process an
amino-terminal precursor peptide
from all three chains of type I collagen
(Lenaers et al., 1971). As a conse-
quence, collagen fibrillogenesis was
impaired and skin integrity compro-
mised (Pie´rard and Lapie`re, 1976). The
animal study prompted investigation of
tissues from a young woman born with
bilateral hip dysplasia/dislocation and
very marked joint laxity. Her skin
contained a2(I) chains of type I col-
lagen with an extension at the amino-
terminal end (Lichtenstein et al., 1973;
Steinmann et al., 1980). Although
initially interpreted to result from en-
zymatic deficiency, studies later
showed that the woman had a hetero-
zygous splice donor mutation in intron
6 of one COL1A2 allele that led to exon
skipping and loss of the sequence that
contained both the propeptide clea-
vage site and the amino-terminal non-
helical cross-link site (Steinmann et al.,
1980). Consistent with this finding,
autosomal dominant inheritance was
soon recognized and mutations in the
COL1A1 gene that led to loss of the
sequences of the homologous exon 6
were found in other affected indivi-
duals (Byers et al., 1997). Although the
outcomes of mutations in the preceding
acceptor site and succeeding donor site
differ in detail, both lead to the same
phenotype. Fewer individuals have
COL1A1 mutations because COL1A1
donor site mutations lead to use of a
cryptic donor site or intron inclusion,
each of which leads to a frame shift,
premature termination codon, mRNA
instability, and an osteogenesis imper-
fecta phenotype. More than 20 years
after the basis of dermatosparaxis
was explained, a human form of the
disorder (then called EDS VIIC) was
identified (Nusgens et al., 1992;
Smith et al., 1992) and shown to result
from biallelic mutations in ADAMTS2,
which encodes the procollagen 1
N-proteinase (Colige et al., 1999).
Variation in the clinical picture reflec-
ted the presence of missense mutations
rather than the early identified non-
sense mutations (Colige et al., 2004).
The early biochemical discovery
phase culminated with the demonstra-
tion that alteration in the amount of
type III procollagen produced was the
underlying cause of EDS type IV, the
Sack Barabas type (Pope et al., 1975).
At first thought to be recessive because
of its rarity, an isolated individual in a
family, and apparent decrease in pro-
duction of type III procollagen by cells
from the parents (Pope et al., 1977),
subsequent analyses of the COL3A1
gene has shown that this is a dominant
disorder (Tsipouras et al., 1986). A
single example of bi-allelic mutations
has been identified out of more than
600 families studied (Plancke et al.,
2009). Some mutations result in failure
to secrete type III procollagen from
fibroblasts and accumulation of the
protein in the rough ER and marked
alteration in dermal structure that led to
the idea that type III collagen formed a
scaffold on which type I fibrillogenesis
occurred (Holbrook and Byers, 1981).
A large clinical study proved it difficult
to identify clear genotype phenotype
correlations (Pepin et al., 2000). Recent
studies, however, make it clear that
heterozygosity for a null mutation in
COL3A1 endows an individual with an
extended natural history compared
with the effects of missense and exon
skipping mutations (Leistritz et al.,
2011).
EDS type I/II proved to be more
difficult than expected to solve at the
molecular level. Ultrastructural studies
of the skin showed that there were
dramatic alterations in the large dermal
collagen fibrils, with variation in fibril
diameter and aggregate formation
(Vogel et al., 1979). Despite this,
linkage studies in families excluded type
I collagen genes as candidates (Sokolov
et al., 1991; Wordsworth et al., 1991). It
was the finding of an X:9 chromosomal
translocation in a woman with EDS
type I and skin pigment alteration
with identification of a breakpoint in
one COL5A1 allele that shed light upon
the molecular basis of the disorder
(Toriello et al., 1996). At the same time,
linkage studies and sequencing of both
COL5A1 and COL5A2 led to the
identification of mutations in individuals
with EDS type I/II (Burrows et al., 1996;
Nicholls et al., 1996; Wenstrup et al.,
1996). Most affected individuals studied
had mutations that led to instability of
mRNA derived from one COL5A1 allele
(Schwarze et al., 2000; Wenstrup et al.,
2000; Malfait et al., 2005). A critical
role of type V collagen in fibril nuclea-
tion was established in homozygous
COL5A1–knockout mice that failed to
survive embryogenesis because no large
collagen fibrils were assembled (Wenstrup
et al., 2004).
Although often cited to suggest that
only about half of affected individuals
with EDS type I or EDS type II (the
previous gravis and mitis type and
future ‘‘classical type’’) have mutations
in type V collagen genes (Malfait et al.,
2005), a recent study using more con-
sistent clinical diagnosis places this
number closer to 90% (Symoens et al.,
2012). Although genetic studies failed
to demonstrate that mutations in type I
collagen genes could cause EDS type I/
II (Sokolov et al., 1991; Wordsworth
et al., 1991), biochemical analysis of
type I collagens synthesized in culture
succeeded. Several individuals with
substitutions of arginine by cysteine
within the triple helical domain of
proa1(I) chains of type I collagen,
encoded by COL1A1, had a clinical
picture of EDS type I/II and also
developed aortic aneurysms or dissec-
tion (Nuytinck et al., 2000; Malfait
et al., 2007). In addition, homozygosity
or compound heterozygosity for
COL1A2-null mutations were found in
several people who had a clinical
presentation with polyvalvular cardiac
involvement, moderate joint hypermo-
bility, skin hyperextensibility, and lim-
ited bruising (Schwarze et al., 2004;
Malfait et al., 2006). Nonetheless,
mutations in type I collagen genes
account for only a small fraction of
patients with EDS type I/II.
By the mid 1990s there had been a
profusion of single case reports that
tried to define additional types of EDS,
most of which relied largely on clinical
differentiation in single systems and
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were not substantiated by compre-
hensive genetic or biochemical studies.
Few survived the later purge done to
help stabilize a classification. Notable
among the survivors, but not inclu-
ded in the later classification, is what
became known as a progeroid type of
EDS in which features of early aging
accompanied significant hypermobility
and appeared to result from defective
glycosaminoglycan addition to several
proteoglycans (Herna´ndez et al., 1986)
(Quentin et al., 1990), ultimately shown
to result from mutations in B4GALT7
(Okajima et al., 1999) (Faiyaz-Ul-Haque
et al., 2004). The target matrix proteins
are probably not limited to decorin and
biglycan, but the lack of posttransla-
tional modification presumably affects
their function (Go¨tte and Kresse, 2005).
The hope to restore order, similar to
that brought by Beighton’s studies
of the 1960s, led to a gathering of
interested clinicians and geneticists at
Villefranche in 1997 and the creation
of a new set of clinical and biochem-
ical criteria for the diagnosis of EDS
(Beighton et al., 1998). This new
classification abolished the previous
Roman numerical system and substi-
tuted a ‘‘descriptive’’ nomenclature,
while at the same time banishing some
previous types to an ‘‘other’’ category.
Created before genetic testing for many
disorders became widespread, this
classification is showing its age and is
in sore need of revision. However, any
static classification system may be
challenged by the expanding molecular
characterization of disorders with some
features of EDS. The tensions among a
purely clinical classification, a purely
genetic classification, and a mixed
classification may be difficult to resolve
and could satisfy neither clinicians nor
molecular geneticists in the long run.
The ‘‘post-Villefranche’’ era has
experienced a proliferation of EDS
types distinguished by clinical and
genetic grounds but not yet incorpo-
rated into a coherent classification. The
elegant studies by Burch et al. (1997) of
a child with 21-hydroxylase deficiency
and a form of EDS led to identification
of a new gene, the loss of function of
which explained the connective tissue
manifestations. The active 21-hydroxy-
lase gene (CYP21A) is located centro-
meric to TNXB, which encodes
tenascin X. A copy of the 30 exons of
TNXB (called TNXA) are located on the
centromeric side of CYP21A and a
deletion mediated by the almost exact
sequence identity between the two
tenascin X genes led to 21-hydroxylase
deficiency and loss of function of both
copies of TNXB. A member of the
matrix tenascin protein family, tenascin
X interacts with collagens and other
matrix macromolecules. Tenascin
X–deficient EDS is distinguished from
classical EDS by autosomal recessive
inheritance, absence of abnormal scar-
ring in the presence of profound joint
hypermobility, very hyperextensible
skin, and striking bruising (Schalkwijk
et al., 2001). The presence of signifi-
cant hypermobility in heterozygous
carriers of null mutations suggested
TNXB as a candidate gene in EDS
type III, the hypermobile type. Indeed,
obligate heterozygotes demonstrated
that about 80% of carrier women but
only 20% of carrier men had significant
joint hypermobility (Zweers et al.,
2003) but wider screening failed to
document mutations at sufficient
frequency to account for EDS type III.
The genomic complexity of this region
has proven a significant barrier to
molecular diagnostics for this gene.
GENETIC AND GENOMIC ANALYSIS
IDENTIFIES MORE TYPES OF EDS
AND THEIR GENETIC BASES
Astute observation of distinctive clini-
cal features in consanguineous families
coupled with genomic searches led
to recognition of several forms of EDS
that fall outside the Villefranche classi-
fication system. These include the
spondylocheiro dysplastic form that
results from mutations in SLC39A13
(Fukada et al., 2008; Giunta et al.,
2008). The gene encodes an endoplas-
mic reticulum–located zinc transporter
but additional studies suggested that
transforming growth factor-b signaling
may also be defective, although the
relationship to phenotype is not clear.
Mutations in CHST14 (Malfait et al.,
2010; Miyake et al., 2010), which
encodes dermatan-4-sulfotransferase 1,
confirms the importance of this mod-
ification as a part of matrix stability. The
mutations result in a musculocontrac-
tural form of EDS. Very recently a new
form of EDS characterized by kyphos-
coliosis, myopathy, and hearing impair-
ment was identified that results from
biallelic mutations in FKBP14 (Bau-
mann et al., 2012), a member of the
prolyl cis-trans isomerase family. Muta-
tions in a family member, FKBP10,
result in a form of osteogenesis imper-
fecta (Alanay et al., 2010), perhaps
because of effects on folding of either
the proa chains of type I procollagen
or of lysyl hydroxylases. This type of
mechanism might help explain the
clinical overlaps among one form of
osteogenesis imperfecta, EDS type VI,
Bruck syndrome, and this new form of
EDS. The genetic etiology of another
rare form of EDS associated with peri-
ventricular heterotopia was established
by recognition of the similarity of the
neurology features with that of periven-
tricular heterotopia due to FLNA muta-
tions (Sheen et al., 2005). To date, this is
the only confirmed X-linked form of
EDS. Most reported individuals are
female, consistent with an embryonic
lethal effect in males.
FINAL CONSIDERATIONS
The genomic era promises to shed
additional light on unsolved forms of
EDS. For example, a form of EDS
characterized by joint hypermobility,
easy bruising, and early periodontal
loss without significant inflammation
was defined as EDS type VIII. This was
shown not to result from mutations in
COL3A1 even though some features
were shared. Linkage to a locus on the
short arm of chromosome 12 (12p13)
was identified in a large Swedish family
but excluded in others, consistent with
locus heterogeneity (Rahman et al.,
2003). To date, the molecular etiology
of this form remains to be established.
Similarly, the genetic etiology in the
majority of persons affected with
hypermobile EDS (type III) remains to
be determined. There are a variety of
challenges to dissecting the genetic
causes of hypermobile EDS, including
but not limited to the clinical varia-
bility, seeming sex-related penetrance,
and likely genetic heterogeneity. Iden-
tifying and understanding the clinical
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diversity, genetic etiology, and patho-
physiologic mechanisms of various
forms of EDS will undoubtedly con-
tinue to expand the work of the last
50 years toward understanding the
biology of the extracellular matrix and
the role of the constituent macromole-
cules in human disease.
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